Standout Papers

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disea... 2012 2026 2016 2021 488
  1. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial (2012)
    Martin Reck, Igor Bondarenko et al. Annals of Oncology

Immediate Impact

18 by Nobel laureates 11 from Science/Nature 97 standout
Sub-graph 1 of 21

Citing Papers

Metastasis
2023 Standout
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
2021 StandoutNature
4 intermediate papers

Works of Huiling Lü being referenced

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
2012 Standout

Author Peers

Author Last Decade Papers Cites
Huiling Lü 518 595 359 548 66 1.9k
Jun Shi 330 706 283 293 61 2.0k
Chiara Bolego 246 791 363 247 81 2.8k
Anil Singh 533 497 272 174 60 1.6k
Stefania Marsico 320 618 209 548 53 2.0k
Maria Bertolotto 388 565 246 347 88 2.6k
Liv Thommesen 420 865 243 270 43 1.7k
Shi Yin 748 614 158 296 71 2.2k
Shotaro Nakajima 451 767 169 349 70 2.0k
Junli Liu 772 970 314 197 64 2.2k
Qi Cao 740 812 285 305 71 2.3k

All Works

Loading papers...

Rankless by CCL
2026